Dexmedetomidine alleviates lipopolysaccharide-induced lung injury in Wistar rats

Oncotarget. 2017 Jul 4;8(27):44410-44417. doi: 10.18632/oncotarget.17899.

Abstract

This study aimed to investigate the protective effects of dexmedetomidine on lipopolysaccharide (LPS)-induced lung injury in Wistar rats. 24 female Wistar rats were randomly assigned into 3 groups (n = 8): a control group, a LPS-challenged group, and a LPS plus dexmedetomidine group. Inflammation, oxidative stress, Nrf2/Keap1, and Akt signal were determined. The results showed that LPS caused inflammation and oxidative stress via increasing pro-inflammatory cytokines and oxidative products. Dexmedetomidine treatment alleviated inflammation and oxidative stress in LPS-challenged rats. Nrf2/Keap1 was inhibited and Akt signal was activated in the lung after exposure to LPS, while dexmedetomidine activated Nrf2/Keap1, which further mediated expressions of antioxidant genes. In conclusion, dexmedetomidine alleviated inflammatory response and oxidative stress in LPS-induced lung injury in rats via influencing Nrf2/Keap1 signal.

Keywords: Nrf2; dexmedetomidine; inflammation; lung injury; oxidative stress.

MeSH terms

  • Animals
  • Biomarkers
  • Cytokines / genetics
  • Cytokines / metabolism
  • Dexmedetomidine / administration & dosage
  • Dexmedetomidine / pharmacology*
  • Disease Models, Animal
  • Female
  • Gene Expression Regulation / drug effects
  • Inflammation Mediators / metabolism
  • Lipopolysaccharides / adverse effects*
  • Lung Injury / drug therapy
  • Lung Injury / etiology*
  • Lung Injury / metabolism*
  • Lung Injury / pathology
  • Oxidation-Reduction / drug effects
  • Oxidative Stress / drug effects
  • Oxidative Stress / genetics
  • Rats
  • Rats, Wistar
  • Signal Transduction / drug effects

Substances

  • Biomarkers
  • Cytokines
  • Inflammation Mediators
  • Lipopolysaccharides
  • Dexmedetomidine